Episode Details
Back to Episodes
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
Published 1 year, 4 months ago
Description
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.